Actively Recruiting

Phase 3
Age: 13Years - 18Years
All Genders
NCT05935826

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Led by University of Colorado, Denver · Updated on 2025-08-28

55

Participants Needed

1

Research Sites

114 weeks

Total Duration

On this page

Sponsors

U

University of Colorado, Denver

Lead Sponsor

N

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group. After the 2 month intervention, all participants can continue the study and will all receive the protein supplement for an additional 10-months.

CONDITIONS

Official Title

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Who Can Participate

Age: 13Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 13 to 18 years, Tanner stage 4-5
  • Suspected or diagnosed NAFLD confirmed by fibroscan or liver biopsy within 6 months prior, with less than 5% body weight loss
  • MRI liver fat greater than 5.5%
  • Diagnosis of NAFLD by a hepatologist
  • Sedentary lifestyle with less than 3 hours of moderate exercise per week
  • BMI at or above the 85th percentile for age and gender (overweight or obese)
Not Eligible

You will not qualify if you...

  • Use of medications affecting insulin sensitivity such as metformin, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressants, or HIV medications
  • Currently pregnant or breastfeeding; pregnancy during the study will require withdrawal
  • Severe illness requiring hospitalization within 60 days
  • Diabetes with Hemoglobin A1C above 6.4%
  • BMI percentile below the 85th for age and sex or waist circumference greater than 200 cm
  • Anemia defined as Hemoglobin less than 11 mg/dL
  • Major psychiatric or developmental disorders limiting informed consent
  • Implanted metal devices incompatible with MRI
  • Use of blood pressure medications
  • Liver disease other than NAFLD or AST or ALT levels above 150 IU/L

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Univeristy of Colorado Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

Loading map...

Research Team

Y

Yesenia Garcia Reyes, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here